Blocking a newly discovered olfactory membrane receptor has been shown to reduce platelet reactivity in abdominal aortic aneurysms (AAAs), raising the prospect of therapeutic targeting to stop AAA progression.
New research shows that immune checkpoint inhibitors can enhance cancer-associated thrombosis in murine models of colon carcinoma.
Our early experience reveals a markedly lower rate of thrombosis than prior reports and points away from using D-dimer to exclude thrombus in hospitalized COVID-19 patients.
The five-year grant, led by Keith McCrae, MD, and Alok Khorana, MD, supports the creation of a new risk assessment tool to better predict which cancer patients will develop treatment-related thrombosis.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Findings from a mouse model provide support for a new drug class that acts on gut microbes to reduce platelet responsiveness and thrombosis risk without promoting bleeding or antibiotic resistance.
An FDA advisory panel just recommended approval of what may be the nation’s first bioresorbable stent. Here’s why an ABSORB III trial investigator wasn’t surprised that interim results didn’t find it superior to a standard DES.
Yet another cardiometabolic effect has been linked to the gut microbial metabolite TMAO: increased thrombotic risk stemming from platelet hyperreactivity. The lead Cleveland Clinic researcher discusses the implications.
Cleveland Clinic oncologist Alok Khorana, MD, discusses the appropriateness of cancer screenings in the wake of unprovoked thromboembolisms in a NEJM Editorial.
New analysis of the phase III CATCH trial of blood-thinning treatments identifies two clinical indicators for recurrent venous thromboembolism: tumor venous compression and hepatobiliary cancer.
New developments promise further progress against restenosis and thrombosis after percutaneous vascular interventions. Cleveland Clinic interventionalists share perspectives on three leading developments.